Fresenius Medical Care, the world’s largest provider of dialysis products and services, expects significant sales and earnings growth in 2017. At the Annual General Meeting in Frankfurt today, CEO Rice Powell confirmed the full-year guidance: The company is targeting on a constant currency basis 8 to 10 percent revenue growth and an increase in net income of 7 to 9 percent.

Rice Powell also confirmed Fresenius Medical Care’s long-term financial goals: Revenue of €24 billion is targeted for 2020, corresponding to an average growth rate of about 10 percent. Over the same period, an annual, high single-digit percent increase in net income is also expected.

“Fresenius Medical Care is the world’s largest dialysis company,” Rice Powell said in his speech to the shareholders. “No one sells more dialysis products than we do. No company cares for more dialysis patients than we do. With Care Coordination, we are creating and expanding business areas that are geared towards offering patients comprehensive treatment beyond the dialysis clinic. New business areas like these will provide the foundations for enhanced growth.”

A large shareholder majority of 88.29 percent approved a 20 percent increase in the dividend, from €0.80 to €0.96, the company’s 20th consecutive dividend increase.

Shareholder majorities of 99.82 and 86.51 percent, respectively, approved the actions of the Management and Supervisory Boards in 2016.

At the Annual General Meeting, 76.82 percent of the subscribed capital was represented.

The next Annual General Meeting is scheduled for May 17, 2018.